1118 Umoja series A
BioCentury & Getty Images

Emerging Company Profile

Umoja launches with $53M round to test cell therapy cocktails that expand CAR T cells within patients

Emerging Company Profile: Umoja to test in vivo approach with first-in-human trial next year

The company expects to test its in vivo approach with a first-in-human trial next year.

Nov 19, 2020 | 12:15 AM GMT

Umoja’s

Read the full 606 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE